{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:55:09Z","timestamp":1790938509702,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"DOI":"10.1007\/s41669-026-00684-5","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:07:50Z","timestamp":1790935670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generalized Pustular Psoriasis: A Cost-of-Illness and Health-Related Quality of Life Study in Italy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-6451","authenticated-orcid":false,"given":"Ludovica","family":"Borsoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Armeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa M.","family":"Scopinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"11","key":"684_CR1","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, K\u00f6ks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139. https:\/\/doi.org\/10.1111\/jdv.14386.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"684_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","volume":"12","author":"K Sugiura","year":"2022","unstructured":"Sugiura K. Role of interleukin 36 in generalised pustular psoriasis and beyond. Dermatol Ther (Heidelb). 2022;12(2):315\u201328. https:\/\/doi.org\/10.1007\/s13555-021-00677-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"684_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","volume":"23","author":"SE Choon","year":"2022","unstructured":"Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(1):21\u20139. https:\/\/doi.org\/10.1007\/s40257-021-00654-z.","journal-title":"Am J Clin Dermatol"},{"key":"684_CR4","doi-asserted-by":"publisher","unstructured":"Gisondi P, Bellinato F, Girolomoni G. Clinical characteristics of patients with pustular psoriasis: a single-center retrospective observational study. Vaccines. 2022;10(8):1171. https:\/\/doi.org\/10.3390\/vaccines10081171.","DOI":"10.3390\/vaccines10081171"},{"issue":"10","key":"684_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2022.3142","volume":"158","author":"CL Zema","year":"2022","unstructured":"Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM. Understanding flares in patients with generalized pustular psoriasis documented in US electronic health records. JAMA Dermatol. 2022;158(10):1142\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3142.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"684_CR6","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jdv.14949","volume":"32","author":"K Hoegler","year":"2018","unstructured":"Hoegler K, John A, Handler M, Schwartz R. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645\u201351. https:\/\/doi.org\/10.1111\/jdv.14949.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"684_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/PTT.S181808","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37\u201342. https:\/\/doi.org\/10.2147\/PTT.S181808.","journal-title":"Psoriasis (Auckl)."},{"issue":"4","key":"684_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/11586900-000000000-00000","volume":"12","author":"J Borges-Costa","year":"2011","unstructured":"Borges-Costa J, Silva R, Gon\u00e7alves L, Filipe P, Soares de Almeida L, Gomes MM. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271\u20136. https:\/\/doi.org\/10.2165\/11586900-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"684_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"issue":"Suppl 1","key":"684_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-021-00664-x","volume":"23","author":"M Zheng","year":"2022","unstructured":"Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5\u201312. https:\/\/doi.org\/10.1007\/s40257-021-00664-x.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"684_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamadermatol.2024.0915","volume":"160","author":"SE Choon","year":"2024","unstructured":"Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, Barker J, Morita A, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council. JAMA Dermatol. 2024;160(7):758\u201368. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0915.","journal-title":"JAMA Dermatol"},{"key":"684_CR12","unstructured":"Fabbri P. La psoriasi\u2014Dalla diagnosi clinica alle nuove terapie. Firenze: SEE Edizioni; 2004."},{"issue":"6","key":"684_CR13","first-page":"669","volume":"16","author":"F Augey","year":"2006","unstructured":"Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669\u201373.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"684_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1055\/s-0030-1252022","volume":"73","author":"I Sch\u00e4fer","year":"2011","unstructured":"Sch\u00e4fer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiologie der Psoriasis in Deutschland. Gesundheitswesen. 2011;73(5):308\u201313. https:\/\/doi.org\/10.1055\/s-0030-1252022. (Epidemiology of psoriasis in Germany--analysis of secondary health insurance data).","journal-title":"Gesundheitswesen"},{"issue":"6","key":"684_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bjd.20966","volume":"186","author":"S L\u00f6fvendahl","year":"2022","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. Br J Dermatol. 2022;186(6):970\u20136. https:\/\/doi.org\/10.1111\/bjd.20966.","journal-title":"Br J Dermatol"},{"issue":"3","key":"684_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1159\/000538072","volume":"240","author":"F Prignano","year":"2024","unstructured":"Prignano F, Atzori L, Bellinato F, Damiani G, Galeone C, Mariani P, et al. Epidemiology, characteristics of disease, and unmet needs of patients with generalized pustular psoriasis: a large Italian Delphi consensus. Dermatology. 2024;240(3):414\u201324. https:\/\/doi.org\/10.1159\/000538072.","journal-title":"Dermatology"},{"issue":"3","key":"684_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666x.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352. https:\/\/doi.org\/10.1080\/1744666x.2019.1708193.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"684_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384. https:\/\/doi.org\/10.1111\/ijd.12070.","journal-title":"Int J Dermatol"},{"issue":"1","key":"684_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2341252","volume":"56","author":"JM Norlin","year":"2024","unstructured":"Norlin JM, L\u00f6fvendahl S, Schmitt-Egenolf M. Health-related quality of life in patients with generalized pustular psoriasis\u2014a Swedish register study. Ann Med. 2024;56(1):2341252. https:\/\/doi.org\/10.1080\/07853890.2024.2341252.","journal-title":"Ann Med"},{"issue":"1","key":"684_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"DV Reisner","year":"2022","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(1):65\u201371. https:\/\/doi.org\/10.1007\/s40257-021-00663-y.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"684_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907\u201319. https:\/\/doi.org\/10.1080\/1744666X.2019.1648209.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"684_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370. https:\/\/doi.org\/10.1111\/1346-8138.14523.","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"684_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51\u201364. https:\/\/doi.org\/10.1007\/s40257-021-00658-9.","journal-title":"Am J Clin Dermatol"},{"key":"684_CR24","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/ccid.S407812","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Investig Dermatol. 2023;16:1677\u201390. https:\/\/doi.org\/10.2147\/ccid.S407812.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"684_CR25","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jval.2025.09.254","volume":"28","author":"L Misery","year":"2025","unstructured":"Misery L, Jullien D, Viguier M, Warren RB, Griffiths CEM, Sticherling M, et al. Inefficiencies of off-label therapy in the prevention of generalized pustular psoriasis (GPP) flares: real-world evidence from Europe. Value Health. 2025;28(12):S72\u20133. https:\/\/doi.org\/10.1016\/j.jval.2025.09.254.","journal-title":"Value Health."},{"issue":"1","key":"684_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2025.08.089","volume":"94","author":"B Strober","year":"2026","unstructured":"Strober B, Kwiatkowski H, Lavasani L, Semeco J, Lakshminarasimhan B, Lebwohl M, et al. Real-world treatment patterns in patients with generalized pustular psoriasis: a US-based claims study. J Am Acad Dermatol. 2026;94(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.089.","journal-title":"J Am Acad Dermatol"},{"key":"684_CR27","unstructured":"Food and Drug Administration (FDA). SPEVIGO\u2014highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761244s003lbl.pdf. Accessed on 30 Mar 2024."},{"key":"684_CR28","unstructured":"European Medicines Agency (EMA). Spevigo. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spevigo. Accessed on 23 Nov 2024."},{"issue":"1","key":"684_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-025-00670-3","volume":"15","author":"XQ Seah","year":"2025","unstructured":"Seah XQ, Mohammed M, Ong SC. Economic burden and cost drivers of generalized pustular psoriasis: a systematic review. Health Econ Rev. 2025;15(1):73. https:\/\/doi.org\/10.1186\/s13561-025-00670-3.","journal-title":"Health Econ Rev"},{"issue":"3","key":"684_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/24755303211021786","volume":"6","author":"J Crowley","year":"2021","unstructured":"Crowley J, Golembesky AK, Kotowsky N, Gao R, Bohn RL, Garry EM, et al. Clinical characteristics and healthcare resource utilization in patients with generalized pustular psoriasis: real-world evidence from a large claims-based dataset. J Psoriasis Psoriatic Arthritis. 2021;6(3):151\u20138. https:\/\/doi.org\/10.1177\/24755303211021786.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"5","key":"684_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/03007995.2021.1894108","volume":"37","author":"ML Hanna","year":"2021","unstructured":"Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021;37(5):735\u201342. https:\/\/doi.org\/10.1080\/03007995.2021.1894108.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"684_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/24755303211021779","volume":"6","author":"JM Sobell","year":"2021","unstructured":"Sobell JM, Gao R, Golembesky AK, Kotowsky N, Garry EM, Comerford EO, et al. Healthcare resource utilization and baseline characteristics of patients with generalized pustular psoriasis: real-world results from a large US database of multiple commercial medical insurers. J Psoriasis Psoriatic Arthritis. 2021;6(3):143\u201350. https:\/\/doi.org\/10.1177\/24755303211021779.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"684_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/24755303221079814","volume":"7","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, et al. The disease burden of generalized pustular psoriasis: real-world evidence from CorEvitas\u2019 psoriasis registry. J Psoriasis Psoriatic Arthritis. 2022;7(2):71\u20138. https:\/\/doi.org\/10.1177\/24755303221079814.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"684_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/ptt.s359011","volume":"12","author":"S L\u00f6fvendahl","year":"2022","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Economic burden of generalized pustular psoriasis in Sweden: a population-based register study. Psoriasis (Auckl). 2022;12:89\u201398. https:\/\/doi.org\/10.2147\/ptt.s359011.","journal-title":"Psoriasis (Auckl)."},{"key":"684_CR35","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.6497","volume":"103","author":"S L\u00f6fvendahl","year":"2023","unstructured":"L\u00f6fvendahl S, Norlin JM, Ericson O, Hanno M, Schmitt-Egenolf M. Prolonged sick leave before and after diagnosis of generalized pustular psoriasis: a Swedish population-based register study. Acta Derm Venereol. 2023;103:adv6497. https:\/\/doi.org\/10.2340\/actadv.v103.6497.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"684_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48(10):1463\u201373. https:\/\/doi.org\/10.1111\/1346-8138.16022.","journal-title":"J Dermatol"},{"issue":"11","key":"684_CR37","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/1346-8138.16084","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48(11):1675\u201387. https:\/\/doi.org\/10.1111\/1346-8138.16084.","journal-title":"J Dermatol"},{"key":"684_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdin.2023.03.012","volume":"12","author":"JE Tarride","year":"2023","unstructured":"Tarride JE, Prajapati VH, Lynde C, Blackhouse G. The burden associated with generalized pustular psoriasis: a Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics. JAAD Int. 2023;12:90\u20138. https:\/\/doi.org\/10.1016\/j.jdin.2023.03.012.","journal-title":"JAAD Int"},{"issue":"6","key":"684_CR39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40257-023-00807-2","volume":"24","author":"H-M Wang","year":"2023","unstructured":"Wang H-M, Xu J-M, Jin H-Z. Characteristics and burdens of disease in patients from Beijing with generalized pustular psoriasis and palmoplantar pustulosis: multicenter retrospective cohort study using a regional database. Am J Clin Dermatol. 2023;24(6):991\u20131002. https:\/\/doi.org\/10.1007\/s40257-023-00807-2.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"684_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2025.07.048","volume":"93","author":"M Lebwohl","year":"2025","unstructured":"Lebwohl M, Lakshminarasimhan B, Lavasani L, Semeco J, Gottlieb AB, Strober B. Healthcare resource utilization and economic burden in generalized pustular psoriasis (GPP) among U.S. adults: a large claims database analysis. J Am Acad Dermatol. 2025;93(5):1341\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2025.07.048.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"684_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/24755303251317193","volume":"10","author":"MH Noe","year":"2025","unstructured":"Noe MH, Lavasani L, Rasouliyan L, Laouri M, Rhoads JLW. Healthcare resource utilization among patients with generalized pustular psoriasis: the impact of flares and disease severity. J Psoriasis Psoriatic Arthritis. 2025;10(2):51-57. https:\/\/doi.org\/10.1177\/24755303251317193.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"issue":"12","key":"684_CR42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s40273-023-01308-0","volume":"41","author":"DA Marshall","year":"2023","unstructured":"Marshall DA, Gerber B, Lorenzetti DL, MacDonald KV, Bohach RJ, Currie GR. Are we capturing the socioeconomic burden of rare genetic disease? A scoping review of economic evaluations and cost-of-illness studies. Pharmacoeconomics. 2023;41(12):1563\u201388. https:\/\/doi.org\/10.1007\/s40273-023-01308-0.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"684_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01815-3","volume":"16","author":"L Garc\u00eda-P\u00e9rez","year":"2021","unstructured":"Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Valc\u00e1rcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. 2021;16(1):178. https:\/\/doi.org\/10.1186\/s13023-021-01815-3.","journal-title":"Orphanet J Rare Dis"},{"key":"684_CR44","doi-asserted-by":"publisher","unstructured":"Armeni P, Cavazza M, Xoxi E, Taruscio D, Kodra Y. Reflections on the importance of cost of illness analysis in rare diseases: a proposal. Int J Environ Res Public Health. 2021;18(3):1101. https:\/\/doi.org\/10.3390\/ijerph18031101.","DOI":"10.3390\/ijerph18031101"},{"issue":"1","key":"684_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","volume":"77","author":"R Tarricone","year":"2006","unstructured":"Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51\u201363. https:\/\/doi.org\/10.1016\/j.healthpol.2005.07.016.","journal-title":"Health Policy"},{"issue":"4","key":"684_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327\u201337. https:\/\/doi.org\/10.3350\/cmh.2014.20.4.327.","journal-title":"Clin Mol Hepatol"},{"key":"684_CR47","unstructured":"Italian National Institute of Statistics (ISTAT). Rivaluta. Available from: http:\/\/rivaluta.istat.it:8080\/Rivaluta\/. Accessed on 23 Nov 2022."},{"issue":"2","key":"684_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2133.1995.tb05019.x","volume":"132","author":"AY Finlay","year":"1995","unstructured":"Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236\u201344. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb05019.x.","journal-title":"Br J Dermatol"},{"key":"684_CR49","unstructured":"Psoriasis Disability Index. Available from: https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality-of-life-questionnaires\/psoriasis-disability-index. Accessed on 28 Oct 2022."},{"issue":"1","key":"684_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10198-016-0789-y","volume":"17","author":"J L\u00f3pez-Bastida","year":"2016","unstructured":"L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Kanavos P, et al. Social\/economic costs and health-related quality of life in patients with scleroderma in Europe. Eur J Health Econ. 2016;17(1):109\u201317. https:\/\/doi.org\/10.1007\/s10198-016-0789-y.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"684_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1061-3","volume":"15","author":"A Angelis","year":"2015","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;15(1):428. https:\/\/doi.org\/10.1186\/s12913-015-1061-3.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"684_CR52","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jval.2019.07.011","volume":"22","author":"R Munk","year":"2019","unstructured":"Munk R, Storheim K, Sm\u00e5stuen MC, Grotle M. Measuring productivity costs in patients with musculoskeletal disorders: measurement properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire. Value Health. 2019;22(12):1410\u20136. https:\/\/doi.org\/10.1016\/j.jval.2019.07.011.","journal-title":"Value Health."},{"issue":"11","key":"684_CR53","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"684_CR54","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774\u201390. https:\/\/doi.org\/10.1111\/jdv.14114.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"684_CR55","unstructured":"Orphanet. Generalized pustular psoriasis. Available from: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=247353. Accessed on 23 Nov 2022."},{"key":"684_CR56","unstructured":"Italian National Institute of Statistics (ISTAT). Dati Istat\u2014Popolazione residente al 1 gennaio. Available from: http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_POPRES1. Accessed on 5 Nov 2022."},{"key":"684_CR57","unstructured":"Italian Medicines Agency (AIFA). Monitoraggio consumi e spesa biosimilari\u2014Dati a giugno 2022. Available from: https:\/\/www.aifa.gov.it\/en\/monitoraggio-consumi-e-spesa-biosimilari. Accessed on 29 Nov 2022."},{"issue":"3","key":"684_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264778","volume":"17","author":"C Donfrancesco","year":"2022","unstructured":"Donfrancesco C, Profumo E, Lo Noce C, Minutoli D, Di Lonardo A, Buttari B, et al. Trends of overweight, obesity and anthropometric measurements among the adult population in Italy: the CUORE Project health examination surveys 1998, 2008, and 2018. PLoS ONE. 2022;17(3):e0264778. https:\/\/doi.org\/10.1371\/journal.pone.0264778.","journal-title":"PLoS ONE"},{"key":"684_CR59","unstructured":"Farmadati Italia. Available from: https:\/\/www.farmadati.it\/. Accessed on 23 Nov 2022."},{"issue":"11","key":"684_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166443","volume":"11","author":"S Mazzuoli","year":"2016","unstructured":"Mazzuoli S, Tricarico D, Demma F, Furneri G, Guglielmi FW. Accelerated infliximab infusion: safety, factors predicting adverse events, patients\u2019 satisfaction and cost analysis. A cohort study in IBD patients. PLoS ONE. 2016;11(11):e0166443. https:\/\/doi.org\/10.1371\/journal.pone.0166443.","journal-title":"PLoS ONE"},{"key":"684_CR61","unstructured":"Italian Ministry of Health. Nomenclatore dell\u2019assistenza specialistica ambulatoriale. Available from: http:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?lingua=italiano&id=1767&area=programmazioneSanitariaLea&menu=lea. Accessed on 29 Nov 2022."},{"key":"684_CR62","unstructured":"Sindacato Medici Italiani (SMI). Scomporre e ricomporre la diversit\u00e0 delle forme contrattuali\u2014Analisi comparata del lavoro medico in Italia. 2014; Available from: https:\/\/www.quotidianosanita.it\/allegati\/allegato4913967.pdf. Accessed on 25 Nov 2022."},{"issue":"26","key":"684_CR63","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2111563.","journal-title":"N Engl J Med"},{"issue":"4","key":"684_CR64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.numecd.2016.01.007","volume":"26","author":"G Veronese","year":"2016","unstructured":"Veronese G, Marchesini G, Forlani G, Saragoni S, Degli Esposti L, Centis E, et al. Costs associated with emergency care and hospitalization for severe hypoglycemia. Nutr Metab Cardiovasc Dis. 2016;26(4):345\u201351. https:\/\/doi.org\/10.1016\/j.numecd.2016.01.007.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"684_CR65","unstructured":"Italian Ministry of Health (Ministero della Salute). Decreto 18 ottobre 2012\u2014Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Allegato 1: \u201cTariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero\u201d. Available from: http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=28\/01\/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001. Accessed on 29 Nov 2022."},{"key":"684_CR66","unstructured":"Agenzia per la Rappresentanza Negoziale delle Pubbliche Amministrazioni. Contratto Collettivo Nazionale di Lavoro Relativo al Personale del Comparto Sanita\u2019 Triennio 2019\u20132021. Available from: https:\/\/www.aranagenzia.it\/documento_pubblico\/contratto-collettivo-nazionale-di-lavoro-relativo-al-personale-del-comparto-sanita-triennio-2019-2021\/. Accessed on 23 Nov 2022."},{"issue":"12","key":"684_CR67","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41591-020-1059-1","volume":"26","author":"DJ Weiss","year":"2020","unstructured":"Weiss DJ, Nelson A, Vargas-Ruiz CA, Gligori\u0107 K, Bavadekar S, Gabrilovich E, et al. Global maps of travel time to healthcare facilities. Nat Med. 2020;26(12):1835\u20138. https:\/\/doi.org\/10.1038\/s41591-020-1059-1.","journal-title":"Nat Med"},{"key":"684_CR68","unstructured":"Agenzia delle Entrate. GU Serie Generale n.317 del 22-12-2020 - Suppl. Ordinario n. 42. Tabelle nazionali dei costi chilometrici di esercizio di autovetture e motoveicoli elaborate dall\u2019ACI. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/12\/22\/20A06899\/sg. Accessed on 23 Nov 2022."},{"issue":"6","key":"684_CR69","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40258-018-0416-4","volume":"16","author":"J Pike","year":"2018","unstructured":"Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765\u201378. https:\/\/doi.org\/10.1007\/s40258-018-0416-4.","journal-title":"Appl Health Econ Health Policy"},{"key":"684_CR70","unstructured":"Eurostat. Median hourly earnings, all employees. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/EARN_SES_PUB2S__custom_4130165\/default\/table?lang=en. Accessed on 20 Nov 2022."},{"issue":"1","key":"684_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0168-8510(99)00028-7","volume":"48","author":"WB Brouwer","year":"1999","unstructured":"Brouwer WB, Koopmanschap MA, Rutten FF. Productivity losses without absence: measurement validation and empirical evidence. Health Policy. 1999;48(1):13\u201327. https:\/\/doi.org\/10.1016\/s0168-8510(99)00028-7.","journal-title":"Health Policy"},{"issue":"6","key":"684_CR72","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Roijen LH-V. The iMTA Productivity Cost Questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753\u20138. https:\/\/doi.org\/10.1016\/j.jval.2015.05.009.","journal-title":"Value Health."},{"key":"684_CR73","unstructured":"Italian National Institute of Statistics (ISTAT). Occupati e disoccupati. Available from: https:\/\/www.istat.it\/comunicato-stampa\/occupati-e-disoccupati-dati-provvisori-febbraio-2023\/. Accessed on 17 May 2023."},{"issue":"1","key":"684_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J","volume":"5","author":"J Posnett","year":"1996","unstructured":"Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 1996;5(1):13\u201323. https:\/\/doi.org\/10.1002\/(SICI)1099-1050(199601)5:1%3c13::AID-HEC182%3e3.0.CO;2-J.","journal-title":"Health Econ"},{"issue":"6","key":"684_CR75","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.a.61124","volume":"179","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885\u201392. https:\/\/doi.org\/10.1002\/ajmg.a.61124.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"684_CR76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/gt.2017.29","volume":"24","author":"D Julkowska","year":"2017","unstructured":"Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24(9):562\u201371. https:\/\/doi.org\/10.1038\/gt.2017.29.","journal-title":"Gene Ther"},{"issue":"10","key":"684_CR77","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"H Bachelez","year":"2022","unstructured":"Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033\u201347. https:\/\/doi.org\/10.1080\/1744666X.2022.2116003.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"684_CR78","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2147\/tcrm.s2740","volume":"4","author":"G Colombo","year":"2008","unstructured":"Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4(2):559\u201368. https:\/\/doi.org\/10.2147\/tcrm.s2740.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"684_CR79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jdv.19530","volume":"38","author":"SE Choon","year":"2024","unstructured":"Choon SE, De La Cruz C, Wolf P, Jha RK, Fischer KI, Goncalves-Bradley DC, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2024;38(2):265\u201380. https:\/\/doi.org\/10.1111\/jdv.19530.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"684_CR80","doi-asserted-by":"publisher","first-page":"1295973","DOI":"10.3389\/fmed.2023.1295973","volume":"10","author":"G Coscarella","year":"2024","unstructured":"Coscarella G, Falco GM, Palmisano G, Ippoliti E, De Luca E, Gori N, et al. Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled. Front Med (Lausanne). 2024;10:1295973. https:\/\/doi.org\/10.3389\/fmed.2023.1295973.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"684_CR81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335\u201344. https:\/\/doi.org\/10.1007\/s40273-014-0132-3.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00684-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:07:54Z","timestamp":1790935674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00684-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":81,"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00684-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ludovica Borsoi, Patrizio Armeni, and Annalisa M. Scopinaro have no relevant financial or non-financial interests to disclose. Paolo Gisondi declares the following conflicts of interest (speaker honoraria, advisory board): Almirall, Amgen, Eli Lilly, Abbvie, Sanofi, UCB, Novartis, Janssen. Francesco Costa declares the following financial interests (speaker honorarium): Boehringer Ingelheim.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research involved human participants, and all procedures performed were in accordance with the national ethical standards. Ethics approval for conducting this research was obtained from the Bocconi Research Ethics Committee (approval n. FA000523).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants involved in the study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No data or images that could identify individual patients were collected in this study. Patients were informed that aggregated data would be published and provided consent to this as part of the informed consent process.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All aggregated data supporting the findings of this study are available within the paper and its supplementary materials.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Microsoft Excel model used in this study is not publicly available. Nonetheless, a detailed explanation of the model and inputs used is provided in the main text and supplementary materials.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: Ludovica Borsoi, Patrizio Armeni, Francesco Costa. Methodology: Ludovica Borsoi, Patrizio Armeni, Francesco Costa. Data collection: Ludovica Borsoi, Patrizio Armeni, Francesco Costa, Annalisa M. Scopinaro, Paolo Gisondi. Formal analysis: Ludovica Borsoi. Writing\u2014original draft preparation: Ludovica Borsoi. Writing\u2014review and editing: Ludovica Borsoi, Patrizio Armeni, Francesco Costa, Annalisa M. Scopinaro, Paolo Gisondi. Funding acquisition: Patrizio Armeni, Francesco Costa. Supervision: Patrizio Armeni, Francesco Costa. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}